Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Management of Rising HbA1c in Diabetic Patients

Assessment and Diagnosis

  • An HbA1c of 6.3% indicates prediabetes or early diabetes according to diagnostic criteria (5.7-6.4% is considered prediabetic range) 1
  • The significant rise from 5.2% to 6.3% over just three months represents concerning glycemic deterioration that requires intervention 1
  • Regular HbA1c monitoring every 3 months is recommended until acceptable glycemic targets are achieved 1

Treatment Approach

  • Metformin is the preferred initial pharmacological agent for type 2 diabetes if not contraindicated and if tolerated, as recommended by the American College of Physicians 2, 3
  • Lifestyle modifications should be emphasized alongside medication, including dietary changes and increased physical activity, with a target of at least 150 minutes/week of moderate activity 4
  • The American Diabetes Association recommends maintaining HbA1c <7% for most non-pregnant adults with diabetes 1, 2

Medication Selection and Monitoring

  • For patients not on any medication, metformin should be initiated at a low dose (500 mg daily or twice daily) and titrated up to an effective dose (typically 2000 mg/day in divided doses) 2, 4
  • If the patient is already on metformin, consider adding a second agent based on patient characteristics, with options including sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors 5, 6
  • Recheck HbA1c in 3 months to assess treatment efficacy, and proceed to dual therapy if target HbA1c is not achieved 1, 6

Important Considerations

  • A rapid rise in HbA1c warrants investigation for potential causes such as medication changes, illness, or lifestyle changes, as recommended by the American College of Physicians 2
  • For patients with HbA1c levels >9%, initial dual therapy may be considered to more quickly achieve glycemic control, according to the American Diabetes Association 2, 6